268 related articles for article (PubMed ID: 23172312)
1. Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway.
Cortot AB; Repellin CE; Shimamura T; Capelletti M; Zejnullahu K; Ercan D; Christensen JG; Wong KK; Gray NS; Jänne PA
Cancer Res; 2013 Jan; 73(2):834-43. PubMed ID: 23172312
[TBL] [Abstract][Full Text] [Related]
2. Activation of the IGF1R pathway potentially mediates acquired resistance to mutant-selective 3rd-generation EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer.
Park JH; Choi YJ; Kim SY; Lee JE; Sung KJ; Park S; Kim WS; Song JS; Choi CM; Sung YH; Rho JK; Lee JC
Oncotarget; 2016 Apr; 7(16):22005-15. PubMed ID: 26980747
[TBL] [Abstract][Full Text] [Related]
3. Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.
Ercan D; Xu C; Yanagita M; Monast CS; Pratilas CA; Montero J; Butaney M; Shimamura T; Sholl L; Ivanova EV; Tadi M; Rogers A; Repellin C; Capelletti M; Maertens O; Goetz EM; Letai A; Garraway LA; Lazzara MJ; Rosen N; Gray NS; Wong KK; Jänne PA
Cancer Discov; 2012 Oct; 2(10):934-47. PubMed ID: 22961667
[TBL] [Abstract][Full Text] [Related]
4. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
Nakagawa T; Takeuchi S; Yamada T; Nanjo S; Ishikawa D; Sano T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Sekido Y; Uenaka T; Yano S
Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075
[TBL] [Abstract][Full Text] [Related]
5. EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.
Ercan D; Choi HG; Yun CH; Capelletti M; Xie T; Eck MJ; Gray NS; Jänne PA
Clin Cancer Res; 2015 Sep; 21(17):3913-23. PubMed ID: 25948633
[TBL] [Abstract][Full Text] [Related]
6. Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer.
Tricker EM; Xu C; Uddin S; Capelletti M; Ercan D; Ogino A; Pratilas CA; Rosen N; Gray NS; Wong KK; Jänne PA
Cancer Discov; 2015 Sep; 5(9):960-971. PubMed ID: 26036643
[TBL] [Abstract][Full Text] [Related]
7. The combination of irreversible EGFR TKIs and SAHA induces apoptosis and autophagy-mediated cell death to overcome acquired resistance in EGFR T790M-mutated lung cancer.
Lee TG; Jeong EH; Kim SY; Kim HR; Kim CH
Int J Cancer; 2015 Jun; 136(11):2717-29. PubMed ID: 25382705
[TBL] [Abstract][Full Text] [Related]
8. The impact of intermittent versus continuous exposure to EGFR tyrosine kinase inhibitor on selection of EGFR T790M-mutant drug-resistant clones in a lung cancer cell line carrying activating EGFR mutation.
Lee Y; Choi YR; Kim KY; Shin DH
Oncotarget; 2016 Jul; 7(28):43315-43323. PubMed ID: 27270313
[TBL] [Abstract][Full Text] [Related]
9. Early emergence of de novo EGFR T790M gatekeeper mutations during erlotinib treatment in PC9 non-small cell lung cancer cells.
Kim S; Park AK; Cho J
Biochem Biophys Res Commun; 2018 Sep; 503(2):710-714. PubMed ID: 29909007
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor.
Piotrowska Z; Niederst MJ; Karlovich CA; Wakelee HA; Neal JW; Mino-Kenudson M; Fulton L; Hata AN; Lockerman EL; Kalsy A; Digumarthy S; Muzikansky A; Raponi M; Garcia AR; Mulvey HE; Parks MK; DiCecca RH; Dias-Santagata D; Iafrate AJ; Shaw AT; Allen AR; Engelman JA; Sequist LV
Cancer Discov; 2015 Jul; 5(7):713-22. PubMed ID: 25934077
[TBL] [Abstract][Full Text] [Related]
11. Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor.
Ercan D; Zejnullahu K; Yonesaka K; Xiao Y; Capelletti M; Rogers A; Lifshits E; Brown A; Lee C; Christensen JG; Kwiatkowski DJ; Engelman JA; Jänne PA
Oncogene; 2010 Apr; 29(16):2346-56. PubMed ID: 20118985
[TBL] [Abstract][Full Text] [Related]
12. The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor.
Godin-Heymann N; Ulkus L; Brannigan BW; McDermott U; Lamb J; Maheswaran S; Settleman J; Haber DA
Mol Cancer Ther; 2008 Apr; 7(4):874-9. PubMed ID: 18413800
[TBL] [Abstract][Full Text] [Related]
13. Noncovalent wild-type-sparing inhibitors of EGFR T790M.
Lee HJ; Schaefer G; Heffron TP; Shao L; Ye X; Sideris S; Malek S; Chan E; Merchant M; La H; Ubhayakar S; Yauch RL; Pirazzoli V; Politi K; Settleman J
Cancer Discov; 2013 Feb; 3(2):168-81. PubMed ID: 23229345
[TBL] [Abstract][Full Text] [Related]
14. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.
Nguyen KS; Kobayashi S; Costa DB
Clin Lung Cancer; 2009 Jul; 10(4):281-9. PubMed ID: 19632948
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells.
Lee Y; Wang Y; James M; Jeong JH; You M
Mol Carcinog; 2016 May; 55(5):991-1001. PubMed ID: 26052929
[TBL] [Abstract][Full Text] [Related]
16. Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation.
Kim SM; Kwon OJ; Hong YK; Kim JH; Solca F; Ha SJ; Soo RA; Christensen JG; Lee JH; Cho BC
Mol Cancer Ther; 2012 Oct; 11(10):2254-64. PubMed ID: 22891040
[TBL] [Abstract][Full Text] [Related]
17. InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.
Ma Y; Tang N; Thompson RC; Mobley BC; Clark SW; Sarkaria JN; Wang J
Clin Cancer Res; 2016 Apr; 22(7):1767-76. PubMed ID: 26561558
[TBL] [Abstract][Full Text] [Related]
18. NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor.
Galvani E; Sun J; Leon LG; Sciarrillo R; Narayan RS; Sjin RT; Lee K; Ohashi K; Heideman DA; Alfieri RR; Heynen GJ; Bernards R; Smit EF; Pao W; Peters GJ; Giovannetti E
Oncotarget; 2015 Dec; 6(40):42717-32. PubMed ID: 26015408
[TBL] [Abstract][Full Text] [Related]
19. Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer.
Wang W; Li Q; Takeuchi S; Yamada T; Koizumi H; Nakamura T; Matsumoto K; Mukaida N; Nishioka Y; Sone S; Nakagawa T; Uenaka T; Yano S
Clin Cancer Res; 2012 Mar; 18(6):1663-71. PubMed ID: 22317763
[TBL] [Abstract][Full Text] [Related]
20. Oncogene swap as a novel mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor in lung cancer.
Mizuuchi H; Suda K; Murakami I; Sakai K; Sato K; Kobayashi Y; Shimoji M; Chiba M; Sesumi Y; Tomizawa K; Takemoto T; Sekido Y; Nishio K; Mitsudomi T
Cancer Sci; 2016 Apr; 107(4):461-8. PubMed ID: 26845230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
